REG - Poolbeg Pharma PLC - Immunomodulator I Patent Opposition Withdrawal

Poolbeg PharmaAnnouncement

19/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230919:nRSS8374Ma&default-theme=true

RNS Number : 8374M  Poolbeg Pharma PLC  19 September 2023

Poolbeg Pharma plc

 

Immunomodulator I Patent Opposition to be Withdrawn

Important step in continued protection of Poolbeg's patent family

 

19 September 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company targeting diseases with a high unmet medical need,
announces that the opposition to one of its European patents (Immunomodulator
I) that was previously filed by a third party is to be withdrawn.

 

In the pharmaceutical industry it is not unusual for patents to be challenged.
The Immunomodulator I European patent was opposed by a third party
in September 2021. Further to engaging with the opposing party, Poolbeg has
reached an amicable conclusion in relation to the patent dispute without any
financial compensation between the parties. This has resulted in the opposing
party agreeing to withdraw its opposition to the Immunomodulator I European
patent and agreeing not to challenge any of Poolbeg's Immunomodulator I or
Immunomodulator II patents in the future.

 

The Company will be communicating with the European Patent Office ('EPO')
regarding the necessity of continuing with the scheduled hearing in November.
Based on specialist advice received, and the fact that the patent went through
an extensive examination process prior to being granted by the EPO, Poolbeg
continues to have full confidence in the validity and strength of the patent
and will defend its intellectual property to the extent required.

 

Poolbeg has a worldwide licence for POLB 001 for all uses in humans and is
developing a strong IP portfolio with patents in place, including
Immunomodulator I and Immunomodulator II, covering the use of the class of p38
MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of
severe influenza and hypercytokinaemia. The Company has also filed patent
applications to expand its IP around POLB 001 and the use of p38 MAP kinase
inhibitors in new disease areas, such as oncology. This enhances the value and
attractiveness of POLB 001 to potential pharma partners.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "The
favourable resolution of the opposition filed against our Immunomodulator I
European patent is an important outcome for us. We have full confidence in the
strength and validity of our patent portfolio and look forward to continuing
to expand our intellectual property and protecting our pipeline of assets. We
remain committed to addressing global unmet medical needs by driving
innovation in healthcare."

 

Footnote:

Immunomodulator I: Use of p38 MAPK inhibitors for the treatment of severe
influenza

Immunomodulator II: Use of p38 MAPK inhibitors in combination with antiviral
compounds for treatment of severe influenza, and the use of p38 MAPK
inhibitors, alone or in combination with an antiviral agent, for the treatment
of hypercytokinaemia

 

- Ends -

 

Enquiries

 Poolbeg Pharma Plc                                                    +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)      +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                  +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                               +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                      +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg
Pharma has a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
Pharma also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, leading to faster development and greater
commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg Pharma's
existing pipeline, the Company is progressing programmes in oncology and
metabolic syndromes; adding disease areas with significant addressable
markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/) , an industry
leading infectious disease and human challenge trials business, Poolbeg Pharma
has access to knowledge, experience, and clinical data from over 20 years of
human challenge trials. The Company is using these insights to acquire new
assets as well as reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction in p38
MAP kinase driven cytokines in a clinical setting; a first-in-class,
intranasally administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is progressing two Artificial Intelligence (AI) Programmes to add
promising new assets to its pipeline as well as developing an Oral Vaccine
Programme and an Oral Delivery Programme focussing on metabolic syndrome
related diseases.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/) @PoolbegPharma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFFIAAITLIV